1. Increased of fasting active glucagon-like peptide-1 is associated with insulin resistance in patients with hypertriglyceridemia
- Author
-
Wei Wang, Ying Sun, Liang Wang, Lujie Zhao, and Chaolin Li
- Subjects
endocrine system ,medicine.medical_specialty ,Triglyceride ,business.industry ,Endocrinology, Diabetes and Metabolism ,digestive, oral, and skin physiology ,Hypertriglyceridemia ,nutritional and metabolic diseases ,Stepwise regression ,medicine.disease ,Glucagon-like peptide-1 ,Pathogenesis ,chemistry.chemical_compound ,Insulin resistance ,Endocrinology ,chemistry ,Diabetes mellitus ,Internal medicine ,Internal Medicine ,medicine ,In patient ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that facilitates insulin secretion and preserves β cell function. hypertriglyceridemia plays an important role in the pathogenesis of insulin resistance and T2DM. The purpose of this study was to measure fasting active GLP-1 levels in hypertriglyceridemia subjects and analyse the relationship between GLP-1 and insulin resistance. We recruited 146 subjects including 38 diabetes patients with hypertriglyceridemia, 33 diabetes patients without hypertriglyceridemia, 35 hypertriglyceridemia subjects, and 40 healthy subjects as the normal control group. Serum fasting active GLP-1 was tested with ELISA in the four groups, and associations with insulin resistance were analysed. Serum fasting active GLP-1 levels were significantly increased in hypertriglyceridemia subjects with or without T2DM compared with healthy controls, particularly hypertriglyceridemia patients with T2DM (p
- Published
- 2021
- Full Text
- View/download PDF